BACKGROUND: Murine double minute 2 (MDM2) oncoprotein and p14(ARF) tumor suppressor play pivotal roles in regulating p53 and function in the MAPK pathway, which is mutated frequently in differentiated thyroid carcinoma (DTC). We hypothesized that functional polymorphisms in the promoters of MDM2 and p14(ARF) contribute to the interindividual difference in predisposition to DTC. METHODS: MDM2-rs2279744, MDM2-rs937283, p14(ARF)-rs3731217, and p14(ARF)-rs3088440 were genotyped in 303 patients with DTC and 511 cancer-free healthy controls. Multivariate logistic regression analysis was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: MDM2-rs2279744 and p14(ARF)-rs3731217 were associated with a significantly increased risk of DTC (MDM2-rs2279744: TT versus TG/GG; OR, 1.5; 95% CI, 1.1-2.0; p14(ARF)-rs3731217: TG/GG versus TT; OR, 1.7; 95% CI, 1.2-2.3). No association was found for MDM2-rs937283 or p14(ARF)-rs3088440. Individuals carrying 3-4 risk genotypes of MDM2 and p14(ARF) had 2.2 times (95% CI, 1.4-3.5) the risk for DTC of individuals carrying 0-1 risk genotypes (P trend = .021). The combined effect of MDM2 and p14(ARF) on risk of DTC was confined to young subjects (≤ 45 years), nonsmokers, nondrinkers, and subjects with a first-degree family history of cancer. These associations were quite similar in strength when cases were restricted to those with papillary thyroid cancer. CONCLUSION: Our results suggest that polymorphisms of MDM2 and p14(ARF) contribute to the interindividual difference in susceptibility to DTC, either alone or more likely jointly. The observed associations warrant further confirmation in independent studies.
BACKGROUND:Murine double minute 2 (MDM2) oncoprotein and p14(ARF) tumor suppressor play pivotal roles in regulating p53 and function in the MAPK pathway, which is mutated frequently in differentiated thyroid carcinoma (DTC). We hypothesized that functional polymorphisms in the promoters of MDM2 and p14(ARF) contribute to the interindividual difference in predisposition to DTC. METHODS:MDM2-rs2279744, MDM2-rs937283, p14(ARF)-rs3731217, and p14(ARF)-rs3088440 were genotyped in 303 patients with DTC and 511 cancer-free healthy controls. Multivariate logistic regression analysis was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS:MDM2-rs2279744 and p14(ARF)-rs3731217 were associated with a significantly increased risk of DTC (MDM2-rs2279744: TT versus TG/GG; OR, 1.5; 95% CI, 1.1-2.0; p14(ARF)-rs3731217: TG/GG versus TT; OR, 1.7; 95% CI, 1.2-2.3). No association was found for MDM2-rs937283 or p14(ARF)-rs3088440. Individuals carrying 3-4 risk genotypes of MDM2 and p14(ARF) had 2.2 times (95% CI, 1.4-3.5) the risk for DTC of individuals carrying 0-1 risk genotypes (P trend = .021). The combined effect of MDM2 and p14(ARF) on risk of DTC was confined to young subjects (≤ 45 years), nonsmokers, nondrinkers, and subjects with a first-degree family history of cancer. These associations were quite similar in strength when cases were restricted to those with papillary thyroid cancer. CONCLUSION: Our results suggest that polymorphisms of MDM2 and p14(ARF) contribute to the interindividual difference in susceptibility to DTC, either alone or more likely jointly. The observed associations warrant further confirmation in independent studies.
Authors: Amy L Sherborne; Fay J Hosking; Rashmi B Prasad; Rajiv Kumar; Rolf Koehler; Jayaram Vijayakrishnan; Elli Papaemmanuil; Claus R Bartram; Martin Stanulla; Martin Schrappe; Andreas Gast; Sara E Dobbins; Yussanne Ma; Eamonn Sheridan; Malcolm Taylor; Sally E Kinsey; Tracey Lightfoot; Eve Roman; Julie A E Irving; James M Allan; Anthony V Moorman; Christine J Harrison; Ian P Tomlinson; Sue Richards; Martin Zimmermann; Csaba Szalai; Agnes F Semsei; Daniel J Erdelyi; Maja Krajinovic; Daniel Sinnett; Jasmine Healy; Anna Gonzalez Neira; Norihiko Kawamata; Seishi Ogawa; H Phillip Koeffler; Kari Hemminki; Mel Greaves; Richard S Houlston Journal: Nat Genet Date: 2010-05-09 Impact factor: 38.330
Authors: Zhongqiu Wang; Erich M Sturgis; Yang Zhang; Zhigang Huang; Qi Zhou; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2011-12-02 Impact factor: 7.396
Authors: Christopher I Amos; Li-E Wang; Jeffrey E Lee; Jeffrey E Gershenwald; Wei V Chen; Shenying Fang; Roman Kosoy; Mingfeng Zhang; Abrar A Qureshi; Selina Vattathil; Christopher W Schacherer; Julie M Gardner; Yuling Wang; D Tim Bishop; Jennifer H Barrett; Stuart MacGregor; Nicholas K Hayward; Nicholas G Martin; David L Duffy; Graham J Mann; Anne Cust; John Hopper; Kevin M Brown; Elizabeth A Grimm; Yaji Xu; Younghun Han; Kaiyan Jing; Caitlin McHugh; Cathy C Laurie; Kim F Doheny; Elizabeth W Pugh; Michael F Seldin; Jiali Han; Qingyi Wei Journal: Hum Mol Genet Date: 2011-09-17 Impact factor: 6.150
Authors: F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters Journal: EMBO J Date: 1998-09-01 Impact factor: 11.598